Paris, France—Progress in genotyping patients with rheumatoid arthritis (RA) suggests that the amino acid valine at position 11 of the HLA-DRB1 gene appears to be the strongest independent genetic determinant of radiographic damage in this disease.
Montreal, QC—Researchers analyzed studies of patient adherence to daily and weekly medications to evaluate the impact of dosing frequency on medication adherence. Osteoporosis was the condition selected by the investigators because there are many daily and weekly medications available for this indication. Their results showed that patients on weekly regimens are 90% more likely to be adherent than those on daily regimens.
Paris, France—Rheumatologists, patients, and payers in the United States are eager to determine whether biosimilars of expensive biologic therapies for rheumatoid arthritis (RA) and other rheumatic conditions will pass the hurdles of testing for approval by the US FDA regulatory agencies. At the recent 2014 European League Against Rheumatism (EULAR) Congress, 2 separate randomized, double-blind, phase 3 trials showed progress.
A recent retrospective study of 114 patients with hypogonadism has led to the conclusion that men with this condition should be screened with dual-energy x-ray absorptiometry (DEXA) for low bone mineral density (BMD). Almost half of the men who participated in this study with testosterone levels below 300 ng/dL were found in the retrospective chart review to have either osteopenia or osteoporosis.
Adults with childhood systemic lupus erythematosus (cSLE) are significantly less likely to be employed than adults with adult-onset SLE (aSLE), according to a large, prospective, longitudinal study by Erica F. Lawson, MD, Department of Pediatrics, Division of Rheumatology, University of California, San Francisco, and colleagues.
Paris, France—Musculoskeletal conditions (MSKCs), which consist of approximately 150 different diseases, are the main driver of healthcare costs, according to a Dutch study presented at the 2014 European League Against Rheumatism (EULAR) Congress.
Paris, France—Nonadherence to medications is widespread in rheumatologic diseases, but the literature is sparse as to how this impacts healthcare outcomes and costs, according to speakers at the 2014 European League Against Rheumatism Congress.
The first generic versions of Celebrex (celecoxib) capsules, a treatment for patients with rheumatoid arthritis, osteoarthritis, acute pain, and other conditions, have been approved by the FDA, according to a press release by the agency.
Page 1 of 3
Results 1 - 10 of 23
Results 1 - 10 of 23